Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 14, 2021 16:06 ET | Source: Biogen Inc.

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia

The Phase 3 STAR study did not meet primary or key secondary endpointsChoroideremia is a rare inherited retinal disease that results in progressive vision loss, ultimately leading to blindness ...
June 10, 2021 16:06 ET | Source: Biogen Inc.

Biogen Announces Investor Day on September 21, 2021

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that it will hold an Investor Day focused on its broad pipeline across neuroscience and related...
June 10, 2021 07:30 ET | Source: Biogen Inc.

New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy

New data analysis suggests an investigational higher dose of SPINRAZA may lead to clinically meaningful improvements in motor functionA NURTURE study analysis shows 92 percent of children who...
June 07, 2021 13:01 ET | Source: Biogen Inc.

Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™

Programs now available to support patients and families with their treatment journey Collaborations with Veterans Health Administration, CVS Health and NAFC focused on health disparities in...
June 07, 2021 13:00 ET | Source: Biogen Inc.

FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

The accumulation of amyloid beta plaques in the brain is a defining pathology of Alzheimer’s disease In clinical trials, ADUHELM reduced amyloid beta plaques by 59 to 71 percent at 18 months of...
June 01, 2021 07:30 ET | Source: Biogen Inc.

Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)

CAMBRIDGE, Mass. and GUANGZHOU, China, June 01, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced results from the Phase 3 study of...
May 21, 2021 07:30 ET | Source: Biogen Inc.

Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform

Collaboration aims to develop a next-generation AAV production platform to help accelerate Biogen’s efforts to bring novel gene therapies to patients worldwideGinkgo’s synthetic biology expertise may...
May 20, 2021 16:06 ET | Source: Biogen Inc.

Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that its next generation manufacturing facility in Solothurn, Switzerland has received a Good...
May 14, 2021 07:30 ET | Source: Biogen Inc.

Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP

While the Phase 2/3 XIRIUS study did not meet its primary endpoint, data indicated positive trends in several prespecified secondary endpoints, such as a clinically relevant measure of visual...
May 13, 2021 16:06 ET | Source: Biogen Inc.; Envisagenics

Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research

As part of the agreement, Biogen will leverage Envisagenics’ AI platform with the goal of better understanding Central Nervous System diseases CAMBRIDGE, Mass. and NEW YORK, May 13, 2021 (GLOBE...